RRA
PLX icon

Round Rock Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Round Rock Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$417K Buy
192,080
+36,978
+24% +$91.8K 0.06% 217
2025
Q4 		$279K Buy
+155,102
New +$317K 0.04% 280

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Round Rock Advisors's PLX Position: Q1 2026 in Review

Round Rock Advisors increased its Protalix BioTherapeutics (PLX) stake by 24% in Q1 2026, buying an estimated $91.8K and bringing the position to 192,080 shares worth $417K. The position accounts for 0.06% of the portfolio, ranked #217.

Round Rock Advisors first reported a position in PLX in Q4 2025 and has held it in 2 quarters since. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Round Rock Advisors held 192,080 shares of Protalix BioTherapeutics worth $417K as of Q1 2026.
  • Round Rock Advisors bought 36,978 Protalix BioTherapeutics shares in Q1 2026, an estimated $91.8K.
  • Protalix BioTherapeutics made up 0.06% of Round Rock Advisors's portfolio in Q1 2026, its #217 holding.
  • Round Rock Advisors first reported a position in Protalix BioTherapeutics in Q4 2025 and has held it in 2 quarters since.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Round Rock Advisors's 13F filing for Q1 2026, filed 15 May 2026.